$1 a day HIV/AIDS drug regimen
In the early 2000s, KEI’s founder, James Love, advocated to lower the price of HIV/AIDS drugs for patients in developing countries. Love convinced generic manufacturer Cipla to sell the standard 3-drug HIV/AIDS regimen for $1 per day, a breakthrough price that saved — and continues to save — millions of lives. Love’s work culminated in the creation of the Global Fund for HIV/AIDS, TB and Malaria and the President’s Emergency Plan For AIDS Relief (PEPFAR), two of the world’s largest providers of HIV/AIDS treatments.
KEI will host a meeting on the Bilski litigation regarding patents on business methods, on September 10, 2009, from noon to 2:00.
When: Thursday, September 10, 2009 Time: 12:00-2:00pm Location: Knowledge Ecology International (KEI) 1621 Connecticut Ave NW, Suite 500 Washington, DC 20009 Tel +1 202 332 2670The meeting will include presentations by:
James Love and James K. Glassman, Don’t Kill Competition for High-Tech Drugs, Roll Call, Sept. 9, 2009.
KEI Statement on Eshoo/Barton amendment
Some reporting
In May 2009, at the WIPO Standing Committee on Copyright and Related Rights (SCCR) 18th session, the governments of Brazil, Ecuador and Paraguay formally tabled a proposal to WIPO endorsing the World Blind Union’s Treaty for Reading Disabled Persons.
In an August 14, 2009 article in the LA Times, Tom Hamburger provides yet another installment in the ongoing disclosures about a secret White House deal with PhRMA on pharmaceutical pricing.
At KEI Washington, DC offices.
When: Tuesday June 30, 2009
Time: 12:30-2:00pm
Location:
Knowledge Ecology International (KEI)
1621 Connecticut Ave NW, Suite 500
Washington, DC 20009
Tel +1 202 332 2670
Matthew Flynn, a doctoral candidate in Sociology at the University of
Texas at Austin, will be presenting some of his dissertation research on
Brazilian pharmaceutical policies. The topics include Brazil’s use of
compulsory licenses, the Bolar Exception, and production of
anti-retrovirals in public laboratories. Matthew holds a Masters of
Continue Reading
The rollcall for the biosimilars vote in on the Internet here. Based upon the count released by the committee, voting for the Eshoo Amendment were 26 Democrats and 21 Republicans. Voting against were 1 republican (Deal) and 10 Democrats. One Republican did not vote. I have bolded the Nay votes.